



This is a repository copy of *Update on romiplostim and eltrombopag indirect comparison*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/97346/>

Version: Accepted Version

Article:

Cooper, K., Matcham, J., Helme, K. et al. (1 more author) (2014) Update on romiplostim and eltrombopag indirect comparison. *International Journal of Technology Assessment in Health Care*, 30 (1). pp. 129-130. ISSN 0266-4623

<https://doi.org/10.1017/S0266462313000767>

This article has been published in a revised form in *International Journal of Technology Assessment in Health Care* [<https://doi.org/10.1017/S0266462313000767>]. This version is free to view and download for private research and study only. Not for re-distribution, re-sale or use in derivative works. © Cambridge University Press 2014.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

UPDATE ON “ROMIPILOSTIM AND ELTROMBOPAG FOR IMMUNE THROMBOCYTOPENIA: METHODS FOR INDIRECT COMPARISON”

Katy Cooper, *University of Sheffield, UK*
James Matcham, *Amgen Ltd, Cambridge, UK*
Kawitha Helme, *Amgen Ltd, Uxbridge, UK*
Ron Akehurst, *University of Sheffield, UK*

Dear Dr Mäkelä,

In our article “Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison” published in this journal [1], we presented an indirect comparison of the effectiveness of eltrombopag and romiplostim in raising platelet counts in patients with immune thrombocytopenia (ITP). Indirect comparison analyses are recommended by the National Institute for Health and Care Excellence (NICE) in cases where randomized head-to-head studies do not exist, and were used by NICE in their guidance for the eltrombopag Single Technology Appraisal submission [2].

Following publication of our paper, updated data from the eltrombopag RAISE study were included in the evidence package to support the NICE final guidance regarding eltrombopag for the treatment of ITP [2,3]. These updated data included 14 additional patients receiving eltrombopag and 1 additional patient receiving placebo assessed as having an overall platelet response, and 6 additional eltrombopag patients and no additional placebo patients assessed as having a durable platelet response (Table 1). We would like to describe the relevance of our original analyses in light of these new data, such that readers of *International Journal of Technology Assessment in Health Care* are aware of the full range of evidence available for informing health policy decisions on the use of eltrombopag and romiplostim.

Several alternative methods are available for conducting an indirect treatment comparison. Our original article presented analyses using five methods, incorporating either a Bayesian or Bucher approach, and in each case the results indicated that romiplostim significantly improves overall platelet response compared with eltrombopag. We consider the Bayesian method to be a more robust approach than the Bucher method, since the Bayesian method includes all data in a single model that accounts for the heterogeneity between studies and preserves the within-trial randomization. The NICE Evidence Review Group (ERG) also considered the Bayesian analysis to be most appropriate, and used this approach in their review of the NICE eltrombopag submission [4]. Including the new eltrombopag response data, and using the same Bayesian methodology as previously used by us, the ERG found that the results remained consistent with our original analysis (Table 1): the overall platelet response was significantly higher in patients receiving romiplostim than in those receiving eltrombopag (odds ratio 0.15; 95% CI 0.02, 0.84), assuming medium heterogeneity. Also consistent with our original analysis, the ERG found that while the point estimate favoured romiplostim, there was no statistically significant difference in durable response between eltrombopag and romiplostim (odds ratio 0.20; 95% CI 0.01, 2.13).

Results from indirect treatment comparisons between eltrombopag and romiplostim should be interpreted with caution due to heterogeneity between the study designs, patient populations, and

response definitions. Nonetheless, in the absence of head-to-head studies these analyses provide important evidence on the relative efficacy of the two currently available thrombopoietin-mimetics in patients with ITP. Using the same Bayesian approach as in our original paper, an independent research group on behalf of NICE (the ERG) have used updated evidence to demonstrate that the overall platelet response remains statistically significantly greater with romiplostim than with eltrombopag.

Table 1: Comparison of platelet response rates between eltrombopag and romiplostim using updated data from the RAISE study. Odds ratios were calculated using Bayesian methodology [1,4].

	Eltrombopag trial data		Romiplostim trial data		Eltrombopag vs romiplostim OR (95% CI)
	Eltrombopag	Placebo	Romiplostim	Placebo	
Original data					
Overall response	77/135 (57%)	7/62 (11%)	69/83 (83%)	3/42 (7%)	0.11 (0.02, 0.66) [Reference 1]
Durable response	57/135 (42%)	4/62 (6%)	41/83 (49%)	1/42 (2%)	0.15 (0.01, 1.88) [Reference 1]
Updated data					
Overall response	91/135 (67%)	8/62 (13%)	69/83 (83%)	3/42 (7%)	0.15 (0.02, 0.84) [Reference 4]
Durable response	63/135 (47%)	4/62 (6%)	41/83 (49%)	1/42 (2%)	0.20 (0.01, 2.13) [Reference 4]

Response definitions in the romiplostim trials: *overall platelet response* was the percentage of patients with a platelet count $\geq 50 \times 10^9/L$ for at least 4 weeks during the trial, excluding responses within 8 weeks after rescue medications; *durable platelet response* was defined for romiplostim as the percentage of patients with platelet count $\geq 50 \times 10^9/L$ on at least 6 of the last 8 weeks of treatment, with no rescue medications at any time during the trial [1]. Response definitions in the eltrombopag trials: *overall platelet response* was a durable or transient response; *transient response* was platelets $50-400 \times 10^9/L$ for ≥ 4 consecutive weeks during treatment including all data up to time of withdrawal for patients who prematurely withdrew, excluding responses during rescue treatment and up to the time platelet counts fell below $50 \times 10^9/L$ after cessation of rescue treatment; *durable platelet response* was platelets $50-400 \times 10^9/L$ for at least 6 of the last 8 weeks of treatment, excluding premature withdrawals and patients using rescue therapy at any time on treatment [3].

REFERENCES

1. Cooper KL, Fitzgerald P, Dillingham K, Helme K, Akehurst R. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. *Int J Technol Assess Health Care*. 2012;28:249-58.
2. NICE technology appraisal guidance 293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) <http://www.nice.org.uk/nicemedia/live/14228/64570/64570.pdf> (accessed 21 August 2013)
3. National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA): Eltrombopag for adult patients with chronic immune thrombocytopenic purpura (cITP).

<http://guidance.nice.org.uk/TA/WaveR/132/Consultation/EvaluationReport/ManufacturersSubmissions/GlaxoSmithKline/pdf/English> . August 2012 (accessed 21 August 2013).

4. Cummins E, Fielding S, Scott N, Rothnie K, Crowther M, Fraser C, Brazzelli M. Eltrombopag for the treatment of chronic immune thrombocytopenic purpura: A Single Technology Appraisal. <http://www.nice.org.uk/nicemedia/live/13747/62137/62137.pdf> . October 2012 (accessed 21 August 2013)

CONFLICTS OF INTEREST

Katy Cooper and Ron Akehurst report their institute has received funding from Amgen to undertake the original research in reference 1. James Matcham and Kawitha Vardeva are employed by Amgen and own stock and/or shares in the company. James O'Kelly, employed by Amgen Ltd, provided medical writing assistance.